Johnson & Johnson (JNJ)vsWORK Medical Technology Group LTD Ordinary Shares (WOK)
JNJ
Johnson & Johnson
$229.85
+1.10%
HEALTHCARE · Cap: $547.28B
WOK
WORK Medical Technology Group LTD Ordinary Shares
$1.21
+3.42%
HEALTHCARE · Cap: $1.56M
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 978324% more annual revenue ($96.36B vs $9.85M). JNJ leads profitability with a 21.8% profit margin vs -10.9%. JNJ earns a higher WallStSmart Score of 59/100 (C).
JNJ
Buy59
out of 100
Grade: C
WOK
Avoid29
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-43.5%
Fair Value
$160.13
Current Price
$229.85
$69.72 premium
Intrinsic value data unavailable for WOK.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 26 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 27.4%
Generating 1.5B in free cash flow
Reasonable price relative to book value
Areas to Watch
Moderate valuation
Expensive relative to growth rate
Earnings declined 52.9%
Grey zone — moderate risk
Smaller company, higher risk/reward
ROE of -6.5% — below average capital efficiency
Revenue declined 14.4%
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.8% and operating margin at 27.4%.
Bull Case : WOK
The strongest argument for WOK centers on Price/Book.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Bear Case : WOK
The primary concerns for WOK are Altman Z-Score, Market Cap, Return on Equity.
Key Dynamics to Monitor
JNJ profiles as a mature stock while WOK is a turnaround play — different risk/reward profiles.
JNJ is growing revenue faster at 9.9% — sustainability is the question.
JNJ generates stronger free cash flow (1.5B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
JNJ scores higher overall (59/100 vs 29/100), backed by strong 21.8% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →WORK Medical Technology Group LTD Ordinary Shares
HEALTHCARE · MEDICAL DEVICES · USA
WORK Medical Technology Group Ltd is a leading entity in the medical technology sector, dedicated to the research, development, and commercialization of cutting-edge healthcare solutions. The company specializes in advanced medical devices designed to enhance patient outcomes and address critical challenges in global healthcare. Its commitment to quality and innovation, combined with a diverse product portfolio, positions WORK for sustained growth, making it an attractive investment opportunity for institutional investors seeking to engage in transformative advancements within the healthcare landscape.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?